Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Feuerstein is soon going to know what it feels like looking up a flagpole after the birds are coming back from a prune juice party.
This has been mentioned multiple times but some journalists had a NDA. This is quite common when new products are introduced but apparently it happens for trial results too.
The author is just a bloke - you and others are giving him way too much credit for being part of some dark conspiracy - with an agenda against Amarin. As for the actual article he's being intellectually dishonest when he said he seek out top Cardiologists when he was actually cheery picking them. I reserve more contempt for some of the doctors he quoted.
Lets chalk it up to some members practicing reverse psychology. NO ONE would be saying this if there wasn't a modest sell off last week.
Shorten version of ROFLMAO (rolling on the floor laughing my ass off)
I'm going to go out on a limb and predict the PPS will be between $12 (BB's first prediction) and $60 (BB's latest prediction) at the close tomorrow.
The author got the part right about Vascepa but why is it at the end of the article?
"Another study presented at the same meeting examined whether a substance derived from a component of fish oil, known as icosapent ethyl, might reduce adverse events among people who already have cardiovascular risk factors, such as hardening of the arteries, diabetes, or high blood fats known as triglycerides.
Overall, that study found there was a 25 percent risk reduction for patients taking the extract. These patients were less likely to die from heart disease, have a heart attack or stroke, be hospitalized for chest pain or need procedures such as angioplasty, stenting or bypass surgery, researchers reported.
"We are reporting a remarkable degree of risk reduction," says Dr. Deepak Bhatt, who headed the study and is a cardiologist at Brigham and Women's Hospital.
The study, which was also a randomized clinical trial, tracked participants for an average of five years. The volunteers took icosapent ethyl, which is sold under the brand name Vascepa and was developed by the Amarin Corporation, which funded Bhatt's research.
The product is available by prescription only for patients with high triglycerides. But the company is expected to apply for FDA approval within the next year to expand treatment to include all high-risk cardiovascular patients."
We only have 20+ hours to see how dead wrong you're going to be. :)
Don Lloyd-Jones, MD, ScM, vice chair of the program committee for Scientific Sessions 2018
These FUD writers have about as much influence as a butterfly has on the wind especially after yesterday's landmark results. The influence you appear to be giving to these FUD writers is unfathomable to me.
Isn't he the one who got spooked? (by the AF/Herper article)
Thanks for the link!!!
Fellow longs - please put in perspective how exponentially more REACH this article and other stories from far more established media outlets will have over a couple of obscure twitter tales.
"Would be interesting to get JL'S take on all this.
And how about HDG"
Me too!
I'm guessing they'll say there is way too much weight being put on the negative commentary.
BB seems a bit bipolar - on one hand he provides great info and then goes off the rails with his suppositions. When has BB or anyone for that matter been right about predicting the pps?
Interesting the predictions before last week were pie in the sky and now with last week's sell off it's gloom and doom. I don't know - I like to think investors know better then to get rattled by some obscure agenda based articles.
But were the docs aware of the results ahead of time (did they have a NDA)? i.e., were they given all the info to make an informed opinion? Did the author seek out the best cardiologists or the ones to likely fit his agenda?
But the fda agreed to it
If the PPS doesn't spike it'll be because the results weren't as great as we hoped they were.
Your post reminded me of the entertaining flat earth YouTube videos and the alternative reality you need to live in to support that view point.
Not yet. The results would have to be very underwhelming for the PPS to be in the teens after AHA IMHO.
I thought Pyrrhonian stated he wasn't going to post here anymore?
It made some sort of sense before efficacy Reduce-It results were announced to troll this board but what's the point now?
What about a deal agreed to in principal with the close happening in 2019? If so does it get leaked out and what does that do to the PPS?
Yeah, another big difference is Nov 10 is not waiting another 5 years and it's more like a kid anticipating Christmas!
One of my biggest concerns with owning stock in Amarin is the level of disillusion from my follow investors. This is what you would expect from a banana republic.
I wouldn't say it will be a free for all with the wall of patents.
I made my bed in August of 2011 (i.e. when I purchased my Amarin stock) so either my investment eventually pays off or it doesn't. So far it has been a nightmare but of late I at least have some hope. Intellectually I know PT are meaningless but it's nice to theorize if the "ifs" come true there might be some validity to the more lofty PT.
Amarin’s current demise doesn’t prove you were right that a mid-$20 buyout was more realistic than a $35 plus buyout. We may never know the answer to that.
Hey you given up hope that Amarin can prevail over the FDA through appeals or lawsuits or survive till the REUCE-IT results come out?
You don't know if there was ever an offer or not.
We're all hurting here but there's no need to lash out at others. It's your prerogative to start doubting your DD but there’s no need to lay the kool aid verbiage onto others.
Conference Call?
Has this been cancelled? There's no webcast link.
Exactly. The last sentence is not exactly a subtle hint.
"This release may be deemed to constitute attorney advertising."
True, the shutdown has largely been shrugged off by the market. But the U.S. government defaulting on its legal obligations is going to have a huge impact on markets all around the world IMO. Amarin will not be immune from this.
I will be very relieved if this issue is resolved before the Adcom on the 16th.
Am I the only one concerned about what will happen to the markets if the debt limit isn't raised?
I know a positive Adcom outcome and approval in December are key milestones for Amarin but we may be talking really "long" term if the federal government goes into default.
But didn't we already know that Boehner didn't have control over his caucus? I thought the "news" would be if got control over them. But I agree the uncertainty on how the house will proceed over the weekend leading up to Monday isn't what the market is looking for.
For the sake of arguement, lets say Vascepa gets NCE designation before Anchor approval. What impact will this have on your scenarios?
I thought J.Z. made it clear they would need help launching (I know, not really a new launch per J.L. but please bear with my semantics) the Anchor indication. That's what I find so puzzling, does this dilution mean they're going to try to launch completely solo?
Plus, Amarin says they have no information on when and if they get NCE designation but the recent dilution suggests they might have a clue that it's not forthcoming anytime soon.
Intellectually I know I just need to wait it out but emotionally I can't help but feel somewhat stressed at the current pps.
Excellent post as usual for content but you're also an excellent writer when you want to be. Thanks for taking the time to go through the terms of the loan.
Does Adam Feuerstein even have a conscience?
http://www.thestreet.com/story/11918223/1/amarin-trouble-grows-as-does-evidence-against-fish-oils-benefits.html
"Vascepa was not used in the Italian study published Wednesday, but still, the odds of Amarin convincing a large pharmaceutical company to partner up on Vascepa's marketing or acquire the entire company went from low to nearly impossible."
Amarin: These Are Facts
Nice rebuttal article to what Adam Feuerstein stated earlier in the week.
http://seekingalpha.com/instablog/4169971-bondwells/1786021-amarin-these-are-facts?source=kizur
I'm coming over too!